Chamberlain University
NR 546 / NR546
Week 3
Antipsychotics Table
Course: Advanced Pharmacology
, lOMoARcPSD|51648332
Drug name Indication Half-life (T1/2), metabolism Notable side effects (associate to pathway or
Target symptoms: state if positive or negative (CYP 450 enzyme) NT)
effect
Potency (if noted. receptor occupancy if
noted )
Neurotransmitter(s) affected
Typical antipsychotics (conventional)
Haloperidol Target Symptoms: Half-Life: Notable Side Effects:
Bipolar Disorder Decanoate is approx. Neuroleptic-induced deficit
Psychotic disorders 3 weeks syndrome
Behavioral disturbances in dementias Oral: 12-38 hours Akathisia
Delirium w/ Lorazepam Metabolism: Drug-induced Parkinsonism
Schizophrenia CYP1A2 Tardive dyskinesia, Tardive dystonia
Tics and vocal utterances in Tourettes CYP2D6 Risk of potentially irreversible
Syndrome CYP3A4 involuntary dyskinetic movements
Second line treatment of severe may increase with cumulative dose
behavior in children of combative and treatment duration
explosive hyperexcitability Galactorrhea, Amenorrhea
Potency: Dizziness Sedation
High potency first-generation Dry mouth, constipation, urinary
Neurotransmitters: retention, blurred vision
Blocks dopamine 2 receptors, reducing Decreased sweating
positive symptoms of psychosis and Hypotension
possibly combative, explosive, and Tachycardia
hyperactive behaviors Hypertension
Blocks dopamine 2 receptors in the Weight gain
nigrostriatal pathway, improving tics
and other symptoms in Tourette’s
syndrome.
Thioridazine Target Symptoms: Half-Life: Notable Side Effects:
Schizophrenia 21-24 Hours Neuroleptic-induced deficit
Potency: Metabolism: syndrome
Low-potency first-generation CYP450 2D6 Akathisia
Neurotransmitters: Priapism
Blocks dopamine 2 receptors, reducing Drug- induced parkinsonism
positive symptoms of psychosis Tardive dyskinesia
Risk of potentially irreversible
involuntary dyskinetic movements
may increase with cumulative dose
NR 546 / NR546
Week 3
Antipsychotics Table
Course: Advanced Pharmacology
, lOMoARcPSD|51648332
Drug name Indication Half-life (T1/2), metabolism Notable side effects (associate to pathway or
Target symptoms: state if positive or negative (CYP 450 enzyme) NT)
effect
Potency (if noted. receptor occupancy if
noted )
Neurotransmitter(s) affected
Typical antipsychotics (conventional)
Haloperidol Target Symptoms: Half-Life: Notable Side Effects:
Bipolar Disorder Decanoate is approx. Neuroleptic-induced deficit
Psychotic disorders 3 weeks syndrome
Behavioral disturbances in dementias Oral: 12-38 hours Akathisia
Delirium w/ Lorazepam Metabolism: Drug-induced Parkinsonism
Schizophrenia CYP1A2 Tardive dyskinesia, Tardive dystonia
Tics and vocal utterances in Tourettes CYP2D6 Risk of potentially irreversible
Syndrome CYP3A4 involuntary dyskinetic movements
Second line treatment of severe may increase with cumulative dose
behavior in children of combative and treatment duration
explosive hyperexcitability Galactorrhea, Amenorrhea
Potency: Dizziness Sedation
High potency first-generation Dry mouth, constipation, urinary
Neurotransmitters: retention, blurred vision
Blocks dopamine 2 receptors, reducing Decreased sweating
positive symptoms of psychosis and Hypotension
possibly combative, explosive, and Tachycardia
hyperactive behaviors Hypertension
Blocks dopamine 2 receptors in the Weight gain
nigrostriatal pathway, improving tics
and other symptoms in Tourette’s
syndrome.
Thioridazine Target Symptoms: Half-Life: Notable Side Effects:
Schizophrenia 21-24 Hours Neuroleptic-induced deficit
Potency: Metabolism: syndrome
Low-potency first-generation CYP450 2D6 Akathisia
Neurotransmitters: Priapism
Blocks dopamine 2 receptors, reducing Drug- induced parkinsonism
positive symptoms of psychosis Tardive dyskinesia
Risk of potentially irreversible
involuntary dyskinetic movements
may increase with cumulative dose
